Risk factors, atrial fibrillation and thromboembolic events

International Angiology

Volumn 27, Issue 5, 2008, Pages 433-438

  Novo, G ^a   Mansueto, P ^a   La Franca, M L ^a   Di Leo, R ^b   Di Rosa, S ^c   Fazio, G ^a   Mansueto, S ^a   Ferrara, F ^a   Novo, S ^a,d  

^a UNIVERSITY OF PALERMO   (Italy)

^b Sciacca Hospital   (Italy)

^c Villa Sofia Hospital   (Italy)

^d NONE   (Italy)

Author keywords

Atrial fibrillation; Hypertension; Postoperative complications; Thromboembolism

Indexed keywords

ACUTE HEART FAILURE; ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; FIBRINOGEN BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HEART DISEASE; HUMAN; HYPERTENSION; HYPERTHYROIDISM; MAJOR CLINICAL STUDY; MALE; OBESITY; PREVALENCE; RISK FACTOR; SENESCENCE; SMOKING; THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; COHORT STUDIES; DIABETES COMPLICATIONS; FEMALE; FIBRINOGEN; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MIDDLE AGED; OBESITY; RISK FACTORS; SMOKING; THROMBOEMBOLISM; YOUNG ADULT;

EID: 56749136431     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8.
2. Lévy S, Breithardt G, Campbell RW, Camm AJ, Daubert JC, Allessie M et al. Atrial fibrillation: current knowledge and recommendations for management. Working Group on Arrhythmias of the European Society of Cardiology. Eur Heart J 1998;19:1294-320.
3. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis and predisposing conditions for Atrial Fibrillation: population-based estimates. Am J Cardiol 1998;82:2N-9N.
4. Lip GY. Fibrinogen and cardiovascular disorders. QJM 1995;88:155-65.
5. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. ACC/AHA/ESC Guidelines for the management of patients with atrial fibrillation. Am Coll Cardiol 2006;15:e149-246.
6. WHO/ISH Committee. Guidelines for the management of arterial hypertension WHO/ISH. J Hypertens 1999;17:151-83.
7. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
8. Black IW, Chesterman CN, Hopkins AP, Lee LC, Chong BH, Walsh WF. Hematologic correlates of left atrial spontaneous echo contrast and thromboembolism in nonvalvular atrial fibrillation. J Am Coll Cardiol 1993;21:451-7.
9. Peters NS, Schilling RJ, Kanagaratnam P, Markides V. Atrial fibrillation: strategies to control combat and cure. Lancet 2002;359:593-603.
10. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. JAMA 1998;279:1273-7.
11. Laupacis A, Albers G, Dalen J, Dunn MI, Jakobson AK, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest 1998;114:579S-89S.
12. Laguna P, Martn A, Del Arco C, Gargantilla P. Risk factors for stroke and thromboprophylaxis in atrial fibrillation: what happens in daily clinical practice? The GEFAUR-1 Study. Ann Emerg Med 2004;44:3-11.
13. McNamara RL, Brass LM, Drozda JP Jr, Go AS, Halperin JL, Kerr CR et al.; American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Data Standards on Atrial Fibrillation); American Collage of Cardiology; American Heart Association. ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with atrial fibrillation: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Data Standards on Atrial Fibrillation). Circulation 2004;109:3223-43.
14. Ohara K, Inoue H, Nozawa T, Hirai T, Iwasa A, Okumura K et al. Accumulation of risk factors enhances the prothrombotic state in atrial fibrillation. Int J Cardiol 2007;
15. Inoue H, Nozawa T, Hirai T, Iwasa A, Okumura K, Lee JD et al. Accumulation of risk factors increases risk of tbromboembolic events in patients with nonvalvular atrial fibrillation. Circ J 2006;70:651-6.
16. Executive summary of the third report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult treatment Panel III). JAMA 2001;285:2486-97.
17. Yu Y, Suo L, Yu H, Wang C, Tang H. Insulin resistance and endothelial dysfunction in type 2 diabetes patients with or without microalbuminuria. Diabetes Res Clin Pract 2004;65:95-104.
18. Tsang TS, Gersh BJ, Appleton CP, Tajik AJ, Barnes ME, Bailey KR et al. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol 2002;40:1636-44.
19. Tsang TS, Barnes ME, Gersh BJ, Bailey KR, Seward JB. Risks for atrial fibrillation and congestive heart failure in patients >/= 65 years of age, with abnormal left ventricular diastolic relaxation. Am J Cardiol 2004;93:54-8.
20. Asinger RW, Koehler J, Pearce LA, Zabalgoitia M, Blackshear JL, Fenster PE et al. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: II. Dense spontaneous echocardiographic contrast (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study). J Am Soc Echocardiogr 1999;12:1088-96.
21. Goldman ME, Pearce LA, Hart RG, Zabalgoitia M, Asinger RW, Safford R et al. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study). J Am Soc Echocardiogr 1999;12:1080-7.
22. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW, for the Stroke Prevention in Atrial Fibrillation Investigators. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. Stroke 1999;30:1223-9.
23. Cushman M, Psaty BM, Macy E, Bovill EG, Cornell ES, Kuller LH et al. Correlates of thrombin markers in an elderly cohort free of clinical cardiovascular disease. Arterioscler Thromb Vasc Biol 1996; 16:1163-9.
24. Hursting MJ, Stead AG, Crout FV, Horvath BZ, Moore BM. Effects of age, race, sex, and smoking on prothrombin fragment 1.2 in a healthy population. Clin Chem 1993;39:683-6.
25. Lowe GD, Rumley A, Woodward M, Morrison CE, Philippou H, Lane DA et al. Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use. Br J Haematol 1997;97:775-84.
26. Blackshear JL, Pearce LA, Hart RG, Zabalgoitia M, Labovitz A, Asinger RW et al. Aortic plaque in atrial fibrillation: prevalence, predictors, and thromboembolic implications. Stroke 1999;30:834-40.
27. Heppell RM, Berkin KE, McLenachan JM, Davies JA. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non rheumatic atrial fibrillation. Heart 1997;77:407-11.
28. Lip GY, Lip PL, Zarifis J, Watson RD. Bareford D, Lowe GD et al. Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin. Circulation 1996;94:425-31.
29. Healey JS, Connolly SJ. Atrial fibrillation: hypertension as a causative agent, risk factors for complications, and potential therapeutic target. Am J Cardiol 2003;91:9G-14G.
30. Aronow WS, Ahn C, Kronzon I, Gutstein H. Association of left ventricular hypertrophy and chronic atrial fibrillation with the incidence of new thromboembolic stroke in 2384 older persons. Am J Cardiol 1999;84:468-9, A9.
31. Frohlich ED, Apstein C, Chobanian AV, Devereux RB, Dustan HP, Dzau V et al. The heart in hypertension. N Engl J Med 1992;327:998-1008. Erratum in: N Engl J Med 1992;327:1768.
32. Hart RG, Pearce LA, Miller VT, Anderson DC, Rothrock JF, Albers GW et al. Cardioembolic vs. noncardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies. Cerebrovasc Dis 2000;10:39-43.
33. Ylidirir A, Batur MK, Oto A. Hypertension and arrhythmia: blood pressure control and beyond. Europace 2002;4:175-82.
34. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation 2003;108:1772-8.
35. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA 1994;271:840-4.
36. Yamamoto K, Ikeda U, Seino Y, Mito H, Fujikawa H, Sekiguchi H et al. Coagulation activity is increased in the left atrium of patients with mitral stenosis. J Am Coll Cardiol 1995;25:107-12.
37. Peverill RE, Harper RW, Gelman J, Gan TE, Harris G, Smolich JJ. Determinants of increased regional left atrial coagulation activity in patients with mitral stenosis. Circulation 1996;94:331-9.
38. Arboix A, Eroles LG, Massons JB, Oliveres M, Pujades R, Targa C. Atrial fibrillation and stroke: clinical presentation of cardioembolic versus atherothrombotic infarction. Int J Card 2000;73:33-42.